Free Speech Under Seal: FDA Response To Allergan Suit Challenging Off-Label Promotion Restrictions Is Kept Confidential
Executive Summary
For the time being, FDA's response to Allergan's suit claiming First Amendment protection of off-label promotion of Botox is off limits